Short Interest in AstraZeneca PLC (OTCMKTS:AZNCF) Increases By 116.7%

AstraZeneca PLC (OTCMKTS:AZNCF) was the recipient of a significant growth in short interest in the month of December. As of December 31st, there was short interest totalling 127,400 shares, a growth of 116.7% from the December 15th total of 58,800 shares. Based on an average daily trading volume, of 8,500 shares, the short-interest ratio is currently 15.0 days.

Institutional Investors Weigh In On AstraZeneca

A hedge fund recently bought a new stake in AstraZeneca stock. Eagle Bay Advisors LLC bought a new stake in shares of AstraZeneca PLC (OTCMKTS:AZNCF) during the 3rd quarter, according to the company in its most recent Form 13F filing with the SEC. The firm bought 1,001 shares of the company’s stock, valued at approximately $156,000. 40.87% of the stock is currently owned by institutional investors.

AstraZeneca Stock Up 1.8 %

AZNCF traded up $2.37 during trading hours on Thursday, hitting $132.13. The company’s stock had a trading volume of 1,869 shares, compared to its average volume of 2,770. AstraZeneca has a fifty-two week low of $118.16 and a fifty-two week high of $175.00. The company has a 50-day simple moving average of $131.35 and a 200 day simple moving average of $148.43.

AstraZeneca Company Profile

AstraZeneca PLC, a biopharmaceutical company, focuses on the discovery, development, manufacture, and commercialization of prescription medicines. The company's marketed products include Tagrisso, Imfinzi, Lynparza, Calquence, Enhertu, Orpathys, Truqap, Zoladex, Faslodex, Farxiga, Brilinta, Lokelma, Roxadustat, Andexxa, Crestor, Seloken, Onglyza, Bydureon, Fasenra, Breztri, Symbicort, Saphnelo, Tezspire, Pulmicort, Bevespi, and Daliresp for cardiovascular, renal, metabolism, and oncology.